Description du projet
Diagnostic plus rapide de la résistance aux antimicrobiens
L’utilisation abusive des antibiotiques a conduit à l’émergence d’une résistance aux antimicrobiens (RAM) provoquée par des bactéries qui ne peuvent être tuées par les médicaments existants. La RAM compromet les procédures de routine dans les hôpitaux et entraîne un nombre important de décès chaque année. L’objectif du projet Nanosynex, financé par l’UE, est de proposer une technologie microfluidique de rupture qui réduit considérablement le temps de traitement des échantillons et permet un diagnostic plus rapide de la RAM. L’introduction de ce dispositif dans la pratique diagnostique de routine aidera les cliniciens à prendre des décisions plus éclairées et plus précises sur l’antibiothérapie à appliquer à leurs patients.
Objectif
Antimicrobial Resistance (AMR) has been declared as one of today’s biggest global threats as 700,000 people die due AMR.
Inappropriate antibiotic use is widespread. In the general practice, physicians commonly use empirical antibiotic therapy (highly inaccurate), since AST results take too long. Nanosynex product provides a revolutionary ultra-fast AST technology that will disrupt the market by cutting time to results in more than half (from 9 – the fastest - to 4 hours). This will allow physicians to get same-day results (i.e. in less than 5 hours) for AST, a unique feature that will save at least one day of hospitalization per patient and help reducing the spread of resistant bacteria. A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction. Nanosynex Ltd is an Israeli start-up providing health-care systems with a rapid microfluidic diagnostic solution for faster and personalised antibiotic treatment. The company intends to scale up in the European market first, thanks to its strategic partnership with Biosynex, a leading French rapid diagnostic test (RDT) company that has an established distribution network in Europe, Middle East and Africa (60+ countries). Afterwards, Nanosynex will expand internationally. Nanosynex forecast to generates 14.7M€ , and and at EBITDA of 3.4M€ by 2024
Champ scientifique
- natural sciencesbiological sciencesmicrobiologybacteriology
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- engineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
5126112 Bnei Brak
Israël
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.